BANGALORE, Jan 31 (Reuters) - Allergan Inc (AGN.N) bought co-promotion rights on Map Pharmaceuticals Inc’s (MAPP.O) experimental treatment for acute migraine for $60 million in upfront payment, in a move to expand its migraine franchise.
BANGALORE, Jan 31 (Reuters) - Allergan Inc (AGN.N) bought co-promotion rights on Map Pharmaceuticals Inc’s (MAPP.O) experimental treatment for acute migraine for $60 million in upfront payment, in a move to expand its migraine franchise.
